Effect of CCNU on Survival, Objective Remissions and Free Interval in Patients with Malignant Gliomas
Three nitrosourea derivatives have been shown to be active against malignant brain glioma. The EORTC Brain Tumor Group is concerned with the therapeutic effects of one of them — CCNU (1-2-chloroethyl-3-cyclohexyl-l-nitro-sourea) — on three clinical parameters; total survival time, objective remission rates and free interval between surgery and relapse. To meet the difficulties encountered in measuring these different criteria two parallel trials uere performed. The aim of trial 26741 was to study the rate of objective remissions and free interval, the purpose of trial 26742 was to measure the effect of CCNU on survival time.
KeywordsSurvival Time Clinical Parameter Malignant Glioma Supportive Therapy Free Interval
Unable to display preview. Download preview PDF.